Highlight
• Pembrolizumab monotherapy significantly extends progression-free survival compared to carboplatin plus paclitaxel in dMMR advanced or recurrent endometrial cancer.
• Pembrolizumab shows a superior safety profile with fewer grade 3 or higher treatment-related adverse events.
• Overall survival benefit did not reach statistical significance at interim analysis.
• The trial establishes immunotherapy as a promising chemotherapy-free first-line option for this patient subset.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
